Compare CBC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBC | RYTM |
|---|---|---|
| Founded | 1902 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 6.3B |
| IPO Year | 2025 | 2017 |
| Metric | CBC | RYTM |
|---|---|---|
| Price | $35.70 | $92.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $35.20 | ★ $140.53 |
| AVG Volume (30 Days) | ★ 799.1K | 613.7K |
| Earning Date | 10-27-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | 25.90 | ★ 28.34 |
| EPS | ★ 0.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.23 | $66.14 |
| Revenue Next Year | $5.79 | $79.25 |
| P/E Ratio | $38.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $74.50 |
| 52 Week High | $35.98 | $122.20 |
| Indicator | CBC | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 71.38 | 47.91 |
| Support Level | $30.60 | $82.92 |
| Resistance Level | N/A | $91.70 |
| Average True Range (ATR) | 0.94 | 3.01 |
| MACD | 0.27 | 0.97 |
| Stochastic Oscillator | 90.37 | 61.28 |
Central Bancompany Inc is a bank holding company that provides a broad range of retail, corporate, mortgage banking, wealth management, and trust products and services to individuals and businesses. Its operating segments include Consumer, Commercial, and Wealth Management. The company generates the majority of its revenue from the Commercial segment, which provides full-service relationship banking solutions to businesses, agencies, and community organizations, including commercial, small business, and government clients. The segment also offers business payment solutions such as treasury management services, merchant services, and commercial bank card products.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.